Apparent oral midazolam clearance by sex as a measure of CYP3A activity at baseline and after ketoconazole inhibition
Data presented as geometric mean.
Midazolam CL/F (ml/min/kg) | Total (n = 19) | Women (n = 10) | Men (n = 9) |
|---|---|---|---|
| Baseline phase | |||
| Mean (95% CI) | 25.4 (20.7-31.0) | 33.9 (27.9-41.2) | 18.3* (14.7-22.9) |
| Range | 12.2-56.6 | 21.1-56.6 | 12.2-28.8 |
| Variance | 128.8 | 95.8 | 28.9 |
| CV% | 41 | 28 | 28 |
| Inhibition phase | |||
| Mean (95% CI) | 2.7** (2.1-3.4) | 3.6 (2.6-4.9) | 1.9* (1.6-2.4) |
| Range | 1.2-8.5 | 2.2-8.5 | 1.2-3.2 |
| Variance | 3.1** | 4.0** | 0.3** |
| CV% | 58 | 51 | 28 |